Skip to main content

Table 4 Comparison of clinical symptom disappearance rate between Ludangshen and placebo group

From: Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial

Variables FAS analysis PPS analysis
Ludangshen Placebo P value Ludangshen Placebo P value
Fatigue (n) 94 90   92 89  
 Week 1 5 (5.3) 0 (0.0) 0.027 5 (5.4) 0 (0.0) 0.026
 Week 2 35 (5.3) 8 (8.9)  < 0.001 34 (36.7) 8 (9.0)  < 0.001
Anorexia (n) 68 70   67 68  
 Week 1 10 (14.7) 3 (4.3) 0.036 10 (14.9) 3 (4.4) 0.038
 Week 2 39 (57.4) 15 (21.4)  < 0.001 39 (58.2) 14 (20.6)  < 0.001
Distention (n) 43 34   42 33  
 Week 1 10 (23.3) 4 (11.8) 0.194 10 (23.8) 4 (12.1) 0.197
 Week 2 29 (67.4) 12 (35.3) 0.005 29 (69.1) 11 (33.3) 0.002
Loose stools (n) 48 52   48 50  
 Week 1 11 (22.9) 5 (9.6) 0.07 11 (22.9) 5 (10.0) 0.058
 Week 2 32 (66.7) 20 (38.5) 0.005 32 (66.7) 18 (36.0) 0.002
Shortness of breath (n) 50 50   49 49  
 Week 1 0 (0.0) 0 (0.0) 1.000 0 (0.0) 0 (0.0) 1.000
 Week 2 8 (16.0) 3 (6.0) 0.110 8 (16.3) 3 (6.1) 0.110
  1. FAS full analysis set, PPS per protocol set